Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Change in Accured Expenses: 2011-2025

Historic Change in Accured Expenses for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $971,647.

  • Capricor Therapeutics' Change in Accured Expenses rose 168.83% to $971,647 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 2201.34%. This contributed to the annual value of $1.9 million for FY2024, which is 46.35% up from last year.
  • According to the latest figures from Q3 2025, Capricor Therapeutics' Change in Accured Expenses is $971,647, which was down 36.45% from $1.5 million recorded in Q2 2025.
  • Capricor Therapeutics' Change in Accured Expenses' 5-year high stood at $1.7 million during Q4 2024, with a 5-year trough of -$912,456 in Q2 2022.
  • In the last 3 years, Capricor Therapeutics' Change in Accured Expenses had a median value of $501,815 in 2023 and averaged $643,934.
  • Per our database at Business Quant, Capricor Therapeutics' Change in Accured Expenses crashed by 1,291.75% in 2022 and then skyrocketed by 83,134.60% in 2025.
  • Capricor Therapeutics' Change in Accured Expenses (Quarterly) stood at $102,308 in 2021, then skyrocketed by 860.17% to $982,327 in 2022, then plummeted by 155.15% to -$541,709 in 2023, then spiked by 406.44% to $1.7 million in 2024, then soared by 168.83% to $971,647 in 2025.
  • Its Change in Accured Expenses was $971,647 in Q3 2025, compared to $1.5 million in Q2 2025 and $1.3 million in Q1 2025.